β blockade after myocardial infarction: Systematic review and meta regression analysis

British Medical Journal

Volumn 318, Issue 7200, 1999, Pages 1730-1737

  Freemantle, Nick ^a   Cleland, John ^a,b   Young, Philip ^b   Mason, James ^b   Harrison, Jane ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PROPRANOLOL; TIMOLOL;

ACUTE HEART INFARCTION; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0000093848     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Smith J, Channer KS. Increasing prescription of drugs for secondai-)- preention after myocardial infarction. BMJ 1995; 311: 917-8.
2. Kccles M, Bradshaw C. Use of secondary prophylxis against myocardial infarction in die north of England li.MJ 1991 02: 91-2.
3. Viskin S, Ilarron IIV. β -Blockers prevent cardiac dcaü i following myocardial infarction: so why are so many î nfarcl survivors discharge without β -blockcrs? AmJ Cardiol 199G; 78: 821 -2.
4. Vusuf S, Fcto R, Lewis J, Collins R, Sleight P. p-HIockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardio- isc 1985: 27: 335-71.
5. Smith TC, Spiegclhalter DJ, Thomas A. Bayesian approaches to randomeffects meta analysis: a comparati e study. Stats Med 1995; 14: 2685-99.
6. Schulz KF, Chalmcrs I, I layes RJ, Alunan DO. Empirical e idencc of bias: dimensions of mediodological quality associated with estimates of treatment effects in controlled trial.-UM 1995: 273: 408-12.
7. Rotlimaii KJ. Modern fftidftniology. Boston: MA Little and Brown, 19.
8. Robins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large strata models. Biometrics 1936; 42: 311-23.
9. FleissJ, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association l> etwecn exposure to environmental tobacco smoke and lung cancer: a critique Clin Epidemiol 1991 ; 44: 127-39.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Conti oiled din r& 1986: 7: 177-88.
11. Carlin JB. Meta analysis for 2 2 tables: a Bayesian approach Stats Med 1992; l 1: 141-58.
12. Hardy RJ, Thompson SG. A likelihood approach to meta analysis with random effects. Stats Med 1996; 15: 619-29.
13. Spiegclhalter D, Thomas A, Best N, Gilks W. BUGS: Bayesian inference using Gibbs sampling. Version 0.50. Cambridge: Medical Research Council Biostatistics Unit, 1995.
14. loannidisJPA, CappclleriJC, LauJ, Skolnik PR, Melville B, Chalmers TC, el aL Early or deferred zî dovudine therapy in HIV-infcctcd patients without an AIDS defining illness. Ann Intern Med 1995; 122: 856-66.
15. Frecmantle N", Mason JM, Ecdes M. Deriving treatment recommendations from evidence within randomised trials: die role and limitation of meta analysis. Intern] Tecknol Assess Health Care (in press).
16. Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 19SS; n: 349-60.
17. TheThromboIysis in Myocardial Infarction Study Group. Comparison of invasive and conservative strategies after treatment with intracnous tissue plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardiaJ infarction (TIMI) phase II trial. A' EnglJ Metl 19S9; 320: G 18-27.
18. WiIhelmsson C, Vedin JA, Wilhclmsen L,Tibblin G. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol: preliminary results. Lancet 1974; ii: l 157.
19. Fecly J, de Vane PJ, Maclean F> . β -BIockers and sympathomimelics. BMJ 1983: 286: 1043-7.
20. McDevitt DG. The assessment of β -adrenoceptor-blocking drugs in man. ISrJ Clin I'luirmacol 1977; 4: 413-25.
21. Owen A. Intravenous β -blockade in acute myocardial infarction: should be used in combination with thrombolysis. 1IMJ 1998; 317: 226-7.
22. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatclet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. 11MJ 1991308: 81-106.
23. β -Blockcr Pooling Project Research Group. The β -blockcr pooling project (BBPP): subgroup findings fiom randomized trials in post infarction patients. EurllcarlJ 1988; 9: 8-16.
24. Gotü ieb SS, McCartcr RJ. Vogel RA. Effect of β -blockade on mortality among high risk and low risk patients after myocardial infarction. A' Engl J Mcd 1998: 339: 489-97.
25. First International Study of Infarct Survival Collaborate Group Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lajirct 19SG; ii: 57-G7.
26. Doughty RX, Rodgers A, Sharpe X, MacMahon S. Effects of β -blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur llcattj 1997; 18: 560-5.
27. I leidenreich PA, Lee TT, Massie ISM.'EffeU of β -blockade on mortality in patients with heart failure: a mcta analysis of randomized clinical trials. JAm Coll CarJiol 1997 0: 27-31.
28. Cleland JGF, Freemantle X, McGowan J, Clark A. The evidence for β blockers in heart failure. D.IJ 1999; 318: 824-5.
29. Latest trials on statins show large benefits? Lancet 1997350: 1525.
30. The Mulriccntcr Diliazem.Poslinfarction Trial (MDPIT) Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction. XEnglJMed 98; 319: 385-92.
31. Smith P, Vrnesen H, Holme I. The eifect of warfarin on mortality and reinfarction after myocardial infarction. NEnglJMfd 1990: 323: 147-52.
32. Anticoagulants in the Secondary- Prevention of Events in Coronary Thrombosis (ASPECT) Research Group Effect of long term oral anticoagulant treaü nent on mortality and cardiovascular moibidity after mjocardial infarction. Laufet 1991: 343: 499-503.